Literature DB >> 12801529

Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells.

Guray Saydam1, Hikmet Hakan Aydin, Fahri Sahin, Nur Selvi, Gulperi Oktem, Ender Terzioglu, Filiz Buyukkececi, Serdar Bedii Omay.   

Abstract

Interferon-alpha (IFN-alpha)-2b is known to have antiproliferative effects on hematological malignant cells, especially chronic myelogenous leukaemia (CML). However, it can induce cytogenetical remissions in a very small percentage of the patients. Also during interferon therapy, resistance can emerge in the CML clones. K562 is an in vitro model cell line transformed from a Ph positive CML patient. It can be induced to differentiate to granulocytic and/or monocytic lineages with certain molecules. IFN-alpha-2b generally exerts its effects on CML cells by Janus family kinases (Jak/Stat) pathway, mostly through tyrosine kinase system. However, there is almost no data on the relevance of serine/threonine (Ser/Thr) protein phosphatase (PP) system in the interferon induced signal transduction pathways. In this study, we investigated serine/threonine protein phosphatases in the IFN-alpha-2b induced K562 cytotoxicity. Trypan blue dye exclusion test and MTT assay were utilised for determining cytotoxicity. IC(50) of IFN-alpha-2b on K562 cells was found to be 600IU/ml. However, no differentiation was determined by analysis of cell surface antigen expressions. Serine/threonine protein phosphatase inhibitors calyculin A (Cal A) and okadaic acid (OKA) augmented the IFN-alpha-2b induced cytotoxicity. Apoptosis assay by the mono-oligonucleosome detection and acridine orange/propidium iodide dye revealed marked apoptosis underlying cytotoxicity. Phosphatase enzyme assay revealed a gradual increase in protein phosphatase 2A (PP2A) activity during interferon induced cytotoxicity. Conversely, immunoblots showed no change in the expression of PP2A catalytic and regulatory subunits. In conclusion, PP2A plays a role in IFN-alpha-2b induced apoptosis of K562 cells and should be investigated as a new window furthermore.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801529     DOI: 10.1016/s0145-2126(02)00347-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  10 in total

1.  The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.

Authors:  Ryan M De Palma; Stuart R Parnham; Yitong Li; Joshua J Oaks; Yuri K Peterson; Zdzislaw M Szulc; Braden M Roth; Yongna Xing; Besim Ogretmen
Journal:  FASEB J       Date:  2019-03-27       Impact factor: 5.191

2.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

3.  Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Authors:  Joshua J Oaks; Ramasamy Santhanam; Christopher J Walker; Steve Roof; Jason G Harb; Greg Ferenchak; Ann-Kathrin Eisfeld; James R Van Brocklyn; Roger Briesewitz; Sahar A Saddoughi; Kyosuke Nagata; Robert Bittman; Michael A Caligiuri; Omar Abdel-Wahab; Ross Levine; Ralph B Arlinghaus; Alfonso Quintas-Cardama; John M Goldman; Jane Apperley; Alistair Reid; Dragana Milojkovic; Mark T Ziolo; Guido Marcucci; Besim Ogretmen; Paolo Neviani; Danilo Perrotti
Journal:  Blood       Date:  2013-08-07       Impact factor: 22.113

Review 4.  Regulation of PP2A by Sphingolipid Metabolism and Signaling.

Authors:  Joshua Oaks; Besim Ogretmen
Journal:  Front Oncol       Date:  2015-01-15       Impact factor: 6.244

5.  PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.

Authors:  Raúl Rincón; Ion Cristóbal; Sandra Zazo; Oriol Arpí; Silvia Menéndez; Rebeca Manso; Ana Lluch; Pilar Eroles; Ana Rovira; Joan Albanell; Jesús García-Foncillas; Juan Madoz-Gúrpide; Federico Rojo
Journal:  Oncotarget       Date:  2015-02-28

6.  Differences in Toxic Response Induced by Three Variants of the Diarrheic Shellfish Poisoning Phycotoxins in Human Intestinal Epithelial Caco-2 Cells.

Authors:  Antoine Huguet; Olivia Drapeau; Fanny Rousselet; Hélène Quenault; Valérie Fessard
Journal:  Toxins (Basel)       Date:  2020-12-08       Impact factor: 4.546

7.  Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells.

Authors:  María M Amaral; Flavia Sacerdoti; Carolina Jancic; Horacio A Repetto; Adrienne W Paton; James C Paton; Cristina Ibarra
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

8.  Effects of Escherichia coli subtilase cytotoxin and Shiga toxin 2 on primary cultures of human renal tubular epithelial cells.

Authors:  Laura B Márquez; Natalia Velázquez; Horacio A Repetto; Adrienne W Paton; James C Paton; Cristina Ibarra; Claudia Silberstein
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

9.  Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer.

Authors:  I Cristóbal; R Manso; R Rincón; C Caramés; S Zazo; T G Del Pulgar; A Cebrián; J Madoz-Gúrpide; F Rojo; J García-Foncillas
Journal:  Br J Cancer       Date:  2014-07-08       Impact factor: 7.640

10.  Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.

Authors:  Kamilla M E Laidlaw; Samuel Berhan; Suhu Liu; Giovannino Silvestri; Tessa L Holyoake; David A Frank; Bharat Aggarwal; Michael Y Bonner; Danilo Perrotti; Heather G Jørgensen; Jack L Arbiser
Journal:  Oncotarget       Date:  2016-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.